MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 12-15-2022
OncoSec Medical Incorporated Total Assets 2011-2026 | ONCS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OncoSec Medical Incorporated
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | 56.3 M | 29.9 M | 29.9 M | 30.2 M | 15.2 M | 32.4 M | 35.6 M | 39.4 M | 6.51 M | 7.43 M | 5.67 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.3 M | 5.67 M | 25.9 M |
Quarterly Total Assets OncoSec Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.1 M | 14.4 M | 21.9 M | 28 M | 70 M | 45.6 M | 56.3 M | 56.3 M | 19.8 M | 33.9 M | 29.9 M | 29.9 M | 32.2 M | 23.2 M | 29.9 M | 29.9 M | 22.1 M | 32.2 M | 30.2 M | 30.2 M | 24.3 M | 18.7 M | 15.2 M | 15.2 M | 32.9 M | 28.1 M | 32.4 M | 32.4 M | 32.7 M | 30.4 M | 35.6 M | 35.6 M | 19.8 M | 35.7 M | 39.4 M | 39.4 M | 10.7 M | 17.1 M | 6.51 M | 6.51 M | 2.98 M | 5.52 M | 7.43 M | 7.43 M | - | 4.14 M | 5.67 M | 5.67 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70 M | 2.98 M | 25.9 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.85 | 3.24 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 322.18 | -3.36 % | $ 42.2 B | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 4.71 | -0.53 % | $ 766 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
165 M | $ 3.51 | 3.09 % | $ 353 M | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
88.5 M | $ 7.72 | 4.04 % | $ 76.3 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
54.8 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 22.0 | 1.48 % | $ 1.03 B | USA |
 |
CymaBay Therapeutics
CBAY
|
435 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 101.75 | 2.29 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.25 | -12.11 % | $ 144 M | USA |
 |
ContraFect Corporation
CFRX
|
20.7 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
377 M | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.6 | -1.04 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
160 M | $ 4.28 | 0.94 % | $ 458 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.69 | -3.64 % | $ 3.01 B | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.59 | 6.71 % | $ 423 M | Britain |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
35 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
34 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
583 M | $ 33.63 | -0.72 % | $ 2.23 B | USA |